Verition Fund Management
NTLA icon

Verition Fund Management’s Intellia Therapeutics NTLA Stock Holding History

Verition Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,297
Closed -$558K – 3809
2025
Q3 		$558K Sell
32,297
-76,308
-70% -$940K ﹤0.01% 2956
2025
Q2 		$1.02M Sell
108,605
-162,829
-60% -$1.34M ﹤0.01% 2460
2025
Q1 		$1.93M Buy
271,434
+260,253
+2,328% +$2.63M 0.01% 1603
2024
Q4 		$130K Sell
11,181
-83,245
-88% -$1.3M ﹤0.01% 3047
2024
Q3 		$1.94M Buy
94,426
+50,763
+116% +$1.17M 0.01% 1436
2024
Q2 		$977K Buy
+43,663
New +$1.04M 0.01% 1681
2023
Q4 		– Sell
-13,200
Closed -$417K – 2576
2023
Q3 		$417K Buy
+13,200
New +$512K ﹤0.01% 1541
2022
Q2 		– Sell
-6,079
Closed -$442K – 2851
2022
Q1 		$442K Buy
+6,079
New +$515K 0.01% 1960

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management's NTLA Position: Q4 2025 in Review

Verition Fund Management sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 32,297 shares — an estimated $558K sold.

Verition Fund Management first reported a position in NTLA in Q1 2022 and held it in 8 quarters. The position peaked at $1.94M in Q3 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Verition Fund Management reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 32,297 Intellia Therapeutics shares in Q4 2025, an estimated $558K.
  • Verition Fund Management first reported a position in Intellia Therapeutics in Q1 2022 and held it in 8 quarters.
  • Verition Fund Management's Intellia Therapeutics position peaked at $1.94M in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.